EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Bullous pemphigoid burden of disease, management and unmet therapeutic needs

V P Werth iD, D F Murrell, P Joly iD, M Ardeleanu, V Hultsch

Journal of the European Academy of Dermatology and Venereology · 2025-02 · 39 (2) · 290-300

DOI: 10.1111/jdv.20313 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 19.09.2024. Verfasst von V P Werth und 4 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Cost of Illness. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals Inc., Sanofi, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bullous pemphigoid (BP) is an autoimmune blistering disease that can have a profound negative impact on quality of life. BP most often affects the elderly, a population with a high medical burden and special safety concerns. In this review, we outline the BP disease course, diagnosis, epidemiology and comorbidities, and describe tools commonly used to assess BP disease activity and severity and the impact of BP on health‐related quality of life. We also outline biologic treatments currently under investigation for the treatment of BP and highlight the importance of considering safety when treating elderly patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousCost of IllnessHumansQuality of Life

Autor:innen und Institutionen

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
  • St George Hospital, University of New South Wales, Sydney, New South Wales, Australia.
  • Rouen University Hospital and INSERM 1234, Normandy University, Rouen, France.
  • Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
  • Sanofi, Cambridge, Massachusetts, USA.

ORCID-Profile: V P Werth, P Joly

Förderung

  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Regeneron Pharmaceuticals

Zitieren

APA

Werth, V. P., Murrell, D. F., Joly, P., Ardeleanu, M., & Hultsch, V. (2025). Bullous pemphigoid burden of disease, management and unmet therapeutic needs. Journal of the European Academy of Dermatology and Venereology, 39(2), 290-300. https://doi.org/10.1111/jdv.20313

Vancouver

Werth VP, Murrell DF, Joly P, Ardeleanu M, Hultsch V. Bullous pemphigoid burden of disease, management and unmet therapeutic needs. Journal of the European Academy of Dermatology and Venereology. 2025;39(2):290-300. doi:10.1111/jdv.20313

BibTeX
@article{Werth2025,
  author = {Werth, V P and Murrell, D F and Joly, P and Ardeleanu, M and Hultsch, V},
  title = {Bullous pemphigoid burden of disease, management and unmet therapeutic needs},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {2},
  pages = {290--300},
  doi = {10.1111/jdv.20313}
}
Kostenlos starten →